The mTORC1 pathway is activated in various neurological diseases, including tuberous sclerosis, neurodegeneration, and autism136, and can be used as a therapeutic target for these diseases137,138, suggesting that REDD1 expression or activity may be reduced in neurodegenerative diseases. Here, DDIT4 is linked to neurodegenerative disease.